Brief: Alligator Bioscience Receives Waiver For Paediatric Trials Of Mitazalimab
May 20 (Reuters) - Alligator Bioscience AB ATORX.ST: EMA GRANTS WAIVER FOR PAEDIATRIC TRIALS OF MITAZALIMAB WAIVER REMOVES A KEY REQUIREMENT AHEAD OF POTENTIAL FUTURE MARKETING AUTHORIZATION SUBMISSIONS IN THE EUROPEAN UNION Source text: ID:nMFNbgt6sR Further company coverage: ATORX.ST (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Alligator Bioscience AB
See all newsSweden's Alligator Bioscience Q3 sales fall as R&D winds down
Brief: Alligator Bioscience Q3 EBIT SEK -19.3 Million
Brief: Alligator Bioscience Appoints Johan Gileus As CEO
Brief: Alligator Bioscience Announces Final Outcome In Rights Issue
Brief: Alligator Bioscience To Initially Receive SEK 58.8 Mln From Rights Issue